{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:32:35Z","timestamp":1793313155069,"version":"4.5.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Diagnostic Pathology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.semdp.2026.151063","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:30:03Z","timestamp":1791934203000},"page":"151063","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular features of prostate cancer with neuroendocrine differentiation"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6616-584X","authenticated-orcid":false,"given":"Behtash G.","family":"Nezami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0760-3950","authenticated-orcid":false,"given":"Xiaoqi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.semdp.2026.151063_bib0001","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-15-1259","article-title":"Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers","volume":"22","author":"Aparicio","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.semdp.2026.151063_bib0002","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","article-title":"The role of lineage plasticity in prostate cancer therapy resistance","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"24","key":"10.1016\/j.semdp.2026.151063_bib0003","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","article-title":"Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study","volume":"36","author":"Aggarwal","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.semdp.2026.151063_bib0004","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3390\/cancers16030523","article-title":"Molecular mechanisms of prostate cancer development in the Precision medicine era: a comprehensive review","author":"Maekawa","year":"2024","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.semdp.2026.151063_bib0005","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"17\u201318","key":"10.1016\/j.semdp.2026.151063_bib0006","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1101\/gad.315739.118","article-title":"Genetics and biology of prostate cancer","volume":"32","author":"Wang","year":"2018","journal-title":"Genes Dev"},{"issue":"12","key":"10.1016\/j.semdp.2026.151063_bib0007","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1158\/0008-5472.CAN-12-3468","article-title":"Androgen receptor-independent function of FoxA1 in prostate cancer metastasis","volume":"73","author":"Jin","year":"2013","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.semdp.2026.151063_bib0008","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1038\/s41467-020-19328-1","article-title":"Role of specialized composition of SWI\/SNF complexes in prostate cancer lineage plasticity","volume":"11","author":"Cyrta","year":"2020","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.semdp.2026.151063_bib0010","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.21037\/tau-20-1339","article-title":"Epigenetics in prostate cancer: clinical implications","volume":"10","author":"Conteduca","year":"2021","journal-title":"Transl Androl Urol"},{"issue":"5","key":"10.1016\/j.semdp.2026.151063_bib0011","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nrg.2016.13","article-title":"Epigenetic modulators, modifiers and mediators in cancer aetiology and progression","volume":"17","author":"Feinberg","year":"2016","journal-title":"Nat Rev Genet"},{"issue":"2","key":"10.1016\/j.semdp.2026.151063_bib0013","doi-asserted-by":"crossref","first-page":"R35","DOI":"10.1530\/ERC-19-0420","article-title":"The epigenetic and transcriptional landscape of neuroendocrine prostate cancer","volume":"27","author":"Davies","year":"2020","journal-title":"Endocr Relat Cancer"},{"issue":"6113","key":"10.1016\/j.semdp.2026.151063_bib0102","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1227604","article-title":"EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent","volume":"338","author":"Xu","year":"2012","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.semdp.2026.151063_bib0014","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1038\/s41467-019-09784-9","article-title":"LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2\/STAT3 signaling","volume":"10","author":"Luo","year":"2019","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.semdp.2026.151063_bib0015","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4103\/aja.aja_128_18","article-title":"Neuroendocrine cells of prostate cancer: biologic functions and molecular mechanisms","volume":"21","author":"Huang","year":"2019","journal-title":"Asian J Androl"},{"key":"10.1016\/j.semdp.2026.151063_bib0016","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.humpath.2018.11.016","article-title":"Evolving concepts in prostatic neuroendocrine manifestations: from focal divergent differentiation to amphicrine carcinoma","volume":"85","author":"Bellur","year":"2019","journal-title":"Hum Pathol"},{"issue":"5","key":"10.1016\/j.semdp.2026.151063_bib0103","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2022.07.002","article-title":"The 2022 world health organization classification of tumors of the urinary system and male genital organs-part B: prostate and urinary tract tumors","volume":"82","author":"Netto","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.semdp.2026.151063_bib0017","series-title":"WHO Classification of Tumours Editorial Board. Urinary and Male Genital Tumours","article-title":"Tumours of the prostate: introduction","author":"Netto","year":"2022"},{"key":"10.1016\/j.semdp.2026.151063_bib0018","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.humpath.2022.10.007","article-title":"Cytomorphology, immunoprofile, and clinicopathologic correlation of metastatic prostatic carcinoma","volume":"130","author":"Lin","year":"2022","journal-title":"Hum Pathol"},{"issue":"10","key":"10.1016\/j.semdp.2026.151063_bib0019","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1172\/JCI128212","article-title":"Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer","volume":"129","author":"Labrecque","year":"2019","journal-title":"J Clin Investig"},{"issue":"4","key":"10.1016\/j.semdp.2026.151063_bib0020","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ccell.2017.09.003","article-title":"Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling","volume":"32","author":"Bluemn","year":"2017","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.semdp.2026.151063_bib0021","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s12022-025-09871-2","article-title":"Reappraisal of neuroendocrine tumor classification of the prostate gland: translating molecular insights into clinical practice","volume":"36","author":"Lobo","year":"2025","journal-title":"Endocr Pathol"},{"issue":"Suppl 1","key":"10.1016\/j.semdp.2026.151063_bib0104","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41379-021-00943-2","article-title":"Lung neuroendocrine neoplasms: recent progress and persistent challenges","volume":"35","author":"Rekhtman","year":"2022","journal-title":"Mod Pathol"},{"issue":"11","key":"10.1016\/j.semdp.2026.151063_bib0022","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.5858\/2009-0583-RAR.1","article-title":"Neuroendocrine tumors of the lung: an update","volume":"134","author":"Rekhtman","year":"2010","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.semdp.2026.151063_bib0023","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2019.08.011","article-title":"Clinical features of neuroendocrine prostate cancer","volume":"121","author":"Conteduca","year":"2019","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.semdp.2026.151063_bib0024","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/his.14707","article-title":"Neuroendocrine differentiation in the setting of prostatic carcinoma: contemporary assessment of a consecutive series","volume":"81","author":"Gopalan","year":"2022","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.semdp.2026.151063_bib0025","first-page":"26","article-title":"Updates of prostate cancer from the 2022 World Health Organization classification of the urinary and male genital tumors","volume":"3","author":"Guo","year":"2023","journal-title":"J Clin Transl Pathol"},{"issue":"2","key":"10.1016\/j.semdp.2026.151063_bib0026","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/PAP.0000000000000431","article-title":"Treatment-related neuroendocrine prostate carcinoma-diagnostic and molecular correlates","volume":"31","author":"Gopalan","year":"2024","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.semdp.2026.151063_bib0027","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.anndiagpath.2019.06.009","article-title":"Neuroendocrine tumors of genitourinary tract: recent advances","volume":"42","author":"Shehabeldin","year":"2019","journal-title":"Ann Diagn Pathol"},{"issue":"13","key":"10.1016\/j.semdp.2026.151063_bib0028","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/pros.20434","article-title":"Immunohistochemical characterization of neuroendocrine cells in prostate cancer","volume":"66","author":"Huang","year":"2006","journal-title":"Prostate"},{"issue":"S1","key":"10.1016\/j.semdp.2026.151063_bib0029","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1038\/modpathol.2017.164","article-title":"Neuroendocrine tumors of the prostate","volume":"31","author":"Fine","year":"2018","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.semdp.2026.151063_bib0030","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/modpathol.3880044","article-title":"Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors","volume":"13","author":"Agoff","year":"2000","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.semdp.2026.151063_bib0031","doi-asserted-by":"crossref","first-page":"228","DOI":"10.5858\/2001-125-0228-IFTTFA","article-title":"Immunostaining for thyroid transcription factor 1 and cytokeratin 20 aids the distinction of small cell carcinoma from Merkel cell carcinoma, but not pulmonary from extrapulmonary small cell carcinomas","volume":"125","author":"Cheuk","year":"2001","journal-title":"Arch Pathol Lab Med"},{"issue":"4","key":"10.1016\/j.semdp.2026.151063_bib0032","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/PAS.0b013e3181d1d457","article-title":"An immunohistochemical study of cervical neuroendocrine carcinomas: neoplasms that are commonly TTF1 positive and which may express CK20 and P63","volume":"34","author":"McCluggage","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.semdp.2026.151063_bib0033","doi-asserted-by":"crossref","first-page":"e793","DOI":"10.1016\/j.clgc.2017.04.006","article-title":"Contemporary incidence and cancer control outcomes of primary neuroendocrine prostate cancer: a SEER database analysis","volume":"15","author":"Zaffuto","year":"2017","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1016\/j.semdp.2026.151063_bib0034","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12032-021-01473-2","article-title":"De novo neuroendocrine transdifferentiation in primary prostate cancer-a phenotype associated with advanced clinico-pathologic features and aggressive outcome","volume":"38","author":"Abdulfatah","year":"2021","journal-title":"Med Oncol"},{"issue":"6410","key":"10.1016\/j.semdp.2026.151063_bib0036","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aat5749","article-title":"Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage","volume":"362","author":"Park","year":"2018","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.semdp.2026.151063_bib0037","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/PAS.0000000000000208","article-title":"Proposed morphologic classification of prostate cancer with neuroendocrine differentiation","volume":"38","author":"Epstein","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"10.1016\/j.semdp.2026.151063_bib0039","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.5858\/2004-128-e166-LNCCTO","article-title":"Low-grade neuroendocrine carcinoma (carcinoid tumor) of the prostate","volume":"128","author":"Reyes","year":"2004","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"10.1016\/j.semdp.2026.151063_bib0040","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s11255-009-9660-8","article-title":"A pure primary low-grade neuroendocrine carcinoma (carcinoid tumor) of the prostate","volume":"42","author":"Giordano","year":"2010","journal-title":"Int Urol Nephrol"},{"issue":"6","key":"10.1016\/j.semdp.2026.151063_bib0041","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1016\/S0022-5347(05)65024-0","article-title":"Metastatic carcinoid tumor of the prostate","volume":"167","author":"Tash","year":"2002","journal-title":"J Urol"},{"issue":"7","key":"10.1016\/j.semdp.2026.151063_bib0042","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1177\/10668969241228297","article-title":"Primary well-differentiated neuroendocrine tumor\/carcinoid of the prostate: case report and review of literature","volume":"32","author":"Alhamar","year":"2024","journal-title":"Int J Surg Pathol"},{"issue":"7","key":"10.1016\/j.semdp.2026.151063_bib0043","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/pros.24497","article-title":"Clinical, pathologic, and molecular features of amphicrine prostate cancer","volume":"83","author":"Graham","year":"2023","journal-title":"Prostate"},{"issue":"18","key":"10.1016\/j.semdp.2026.151063_bib0044","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1158\/0008-5472.CAN-21-0307","article-title":"RNA splicing factors SRRM3 and SRRM4 distinguish molecular phenotypes of castration-resistant neuroendocrine prostate cancer","volume":"81","author":"Labrecque","year":"2021","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.semdp.2026.151063_bib0045","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/his.13330","article-title":"Prostate carcinoma with amphicrine features: further refining the spectrum of neuroendocrine differentiation in tumours of primary prostatic origin?","volume":"71","author":"Prendeville","year":"2017","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.semdp.2026.151063_bib0046","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/path.3987","article-title":"Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer","volume":"227","author":"Wu","year":"2012","journal-title":"J Pathol"},{"issue":"10","key":"10.1016\/j.semdp.2026.151063_bib0047","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41585-021-00490-0","article-title":"Molecular events in neuroendocrine prostate cancer development","volume":"18","author":"Wang","year":"2021","journal-title":"Nat Rev Urol"},{"issue":"1","key":"10.1016\/j.semdp.2026.151063_bib0048","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s42003-020-01476-1","article-title":"Single-cell analysis supports a luminal-neuroendocrine transdifferentiation in human prostate cancer","volume":"3","author":"Dong","year":"2020","journal-title":"Commun Biol"},{"key":"10.1016\/j.semdp.2026.151063_bib0049","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3389\/fonc.2014.00060","article-title":"The many faces of neuroendocrine differentiation in prostate cancer progression","volume":"4","author":"Terry","year":"2014","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.semdp.2026.151063_bib0050","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1038\/modpathol.2011.56","article-title":"ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin","volume":"24","author":"Williamson","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1016\/j.semdp.2026.151063_bib0051","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1009146","article-title":"A rare case of prostate neuroendocrine tumor: a case report","volume":"12","author":"Teh","year":"2022","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.semdp.2026.151063_bib0052","first-page":"128","article-title":"Function and molecular mechanisms of neuroendocrine cells in prostate cancer","volume":"29","author":"Huang","year":"2007","journal-title":"Anal Quant Cytol Histol"},{"issue":"4","key":"10.1016\/j.semdp.2026.151063_bib0053","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.annonc.2020.02.002","article-title":"Epigenetic modulations and lineage plasticity in advanced prostate cancer","volume":"31","author":"Ge","year":"2020","journal-title":"Ann Oncol"},{"issue":"6320","key":"10.1016\/j.semdp.2026.151063_bib0054","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aah4307","article-title":"SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer","volume":"355","author":"Mu","year":"2017","journal-title":"Science"},{"issue":"48","key":"10.1016\/j.semdp.2026.151063_bib0055","doi-asserted-by":"crossref","first-page":"7142","DOI":"10.1038\/s41388-020-01487-6","article-title":"De novo induction of lineage plasticity from human prostate luminal epithelial cells by activated AKT1 and c-Myc","volume":"39","author":"Kwon","year":"2020","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.semdp.2026.151063_bib0057","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1074\/jbc.M608487200","article-title":"Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer","volume":"282","author":"Wu","year":"2007","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.semdp.2026.151063_bib0058","first-page":"1","article-title":"Widespread activation and critical role of EMT and stemness in the neuroendocrine differentiation of prostate cancer (Review)","volume":"54","author":"Li","year":"2025","journal-title":"Oncol Rep"},{"issue":"6","key":"10.1016\/j.semdp.2026.151063_bib0060","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/stem.1087","article-title":"Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer","volume":"30","author":"Germann","year":"2012","journal-title":"Stem Cells"},{"issue":"4","key":"10.1016\/j.semdp.2026.151063_bib0035","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/iju.13526","article-title":"Clinical and molecular features of treatment-related neuroendocrine prostate cancer","volume":"25","author":"Akamatsu","year":"2018","journal-title":"Int J Urol"},{"issue":"3","key":"10.1016\/j.semdp.2026.151063_bib0061","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1677\/ERC-07-0061","article-title":"Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells","volume":"14","author":"Yuan","year":"2007","journal-title":"Endocr Relat Cancer"},{"issue":"6320","key":"10.1016\/j.semdp.2026.151063_bib0062","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.aah4199","article-title":"Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance","volume":"355","author":"Ku","year":"2017","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.semdp.2026.151063_bib0063","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2011.84","article-title":"Roles of the Polycomb group proteins in stem cells and cancer","volume":"2","author":"Richly","year":"2011","journal-title":"Cell Death Dis"},{"issue":"6","key":"10.1016\/j.semdp.2026.151063_bib0064","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","article-title":"Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets","volume":"1","author":"Beltran","year":"2011","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.semdp.2026.151063_bib0065","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ccell.2016.03.001","article-title":"N-Myc drives neuroendocrine prostate cancer initiated from Human prostate epithelial cells","volume":"29","author":"Lee","year":"2016","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.semdp.2026.151063_bib0066","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1593\/neo.121550","article-title":"Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer","volume":"15","author":"Mosquera","year":"2013","journal-title":"Neoplasia"},{"issue":"5","key":"10.1016\/j.semdp.2026.151063_bib0067","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/pros.24664","article-title":"Diagnosis and management of neuroendocrine prostate cancer","volume":"84","author":"de Kouchkovsky","year":"2024","journal-title":"Prostate"},{"issue":"19","key":"10.1016\/j.semdp.2026.151063_bib0068","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1038\/emboj.2011.328","article-title":"Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer","volume":"30","author":"Sahu","year":"2011","journal-title":"EMBO J"},{"issue":"28","key":"10.1016\/j.semdp.2026.151063_bib0105","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1038\/onc.2017.50","article-title":"FOXA1 inhibits prostate cancer neuroendocrine differentiation","volume":"36","author":"Kim","year":"2017","journal-title":"Oncogene"},{"issue":"21","key":"10.1016\/j.semdp.2026.151063_bib0070","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1158\/0008-5472.CAN-24-1388","article-title":"Neuroendocrine differentiation in prostate cancer requires ASCL1","volume":"84","author":"Rodarte","year":"2024","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.semdp.2026.151063_bib0071","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1038\/s41467-022-29963-5","article-title":"ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer","volume":"13","author":"Nouruzi","year":"2022","journal-title":"Nat Commun"},{"issue":"484","key":"10.1016\/j.semdp.2026.151063_bib0098","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav0891","article-title":"Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer","volume":"11","author":"Puca","year":"2019","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.semdp.2026.151063_bib0074","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/nar\/gkt921","article-title":"REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer","volume":"42","author":"Svensson","year":"2014","journal-title":"Nucleic Acids Res"},{"issue":"20","key":"10.1016\/j.semdp.2026.151063_bib0075","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1158\/1078-0432.CCR-15-0157","article-title":"SRRM4 Expression and the loss of REST activity may promote the emergence of the neuroendocrine phenotype in castration-resistant prostate cancer","volume":"21","author":"Zhang","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.semdp.2026.151063_bib0076","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.stem.2012.12.007","article-title":"The sox family of transcription factors: versatile regulators of stem and progenitor cell fate","volume":"12","author":"Sarkar","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"12","key":"10.1016\/j.semdp.2026.151063_bib0077","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1038\/s41591-018-0241-1","article-title":"ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis","volume":"24","author":"Rotinen","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.semdp.2026.151063_bib0106","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41467-018-08133-6","article-title":"ONECUT2 is a driver of neuroendocrine prostate cancer","volume":"10","author":"Guo","year":"2019","journal-title":"Nat Commun"},{"issue":"30","key":"10.1016\/j.semdp.2026.151063_bib0078","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2014.57.5100","article-title":"Neuroendocrine prostate cancer after hormonal therapy: knowing is half the battle","volume":"32","author":"Tagawa","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3 Pt 2","key":"10.1016\/j.semdp.2026.151063_bib0079","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0022-5347(17)37427-X","article-title":"Chemotherapy for small cell carcinoma of prostatic origin","volume":"147","author":"Amato","year":"1992","journal-title":"J Urol"},{"issue":"10","key":"10.1016\/j.semdp.2026.151063_bib0080","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S1470-2045(19)30408-5","article-title":"Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial","volume":"20","author":"Corn","year":"2019","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.semdp.2026.151063_bib0081","doi-asserted-by":"crossref","first-page":"290","DOI":"10.5534\/wjmh.230177","article-title":"PARP inhibitors in the treatment of prostate cancer: from scientific rationale to clinical development","volume":"42","author":"Kwon","year":"2024","journal-title":"World J Mens Health"},{"issue":"1","key":"10.1016\/j.semdp.2026.151063_bib0107","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41467-023-35880-y","article-title":"CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer","volume":"14","author":"Tsujino","year":"2023","journal-title":"Nat Commun"},{"issue":"23","key":"10.1016\/j.semdp.2026.151063_bib0082","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312628","article-title":"BRCA mutations in prostate cancer: assessment, implications and treatment considerations","volume":"22","author":"Shah","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.semdp.2026.151063_bib0083","doi-asserted-by":"crossref","first-page":"161","DOI":"10.21037\/atm.2018.05.06","article-title":"Prostate cancer in the era of \"omic\" medicine: recognizing the importance of DNA damage repair pathways","volume":"6","author":"Kornberg","year":"2018","journal-title":"Ann Transl Med"},{"issue":"1","key":"10.1016\/j.semdp.2026.151063_bib0084","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-18-1912","article-title":"A Phase II trial of the Aurora Kinase A inhibitor Alisertib for patients with castration-resistant and neuroendocrine prostate cancer: efficacy and biomarkers","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semdp.2026.151063_bib0108","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41391-022-00524-7","article-title":"A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer","volume":"25","author":"Brown","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"10","key":"10.1016\/j.semdp.2026.151063_bib0085","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1158\/0008-5472.CAN-17-3677","article-title":"Heterochromatin protein 1alpha mediates development and aggressiveness of neuroendocrine prostate cancer","volume":"78","author":"Ci","year":"2018","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.semdp.2026.151063_bib0086","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-15-1263","article-title":"The master neural transcription factor BRN2 is an androgen receptor-suppressed driver of neuroendocrine differentiation in prostate cancer","volume":"7","author":"Bishop","year":"2017","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.semdp.2026.151063_bib0087","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.celrep.2015.07.012","article-title":"The placental gene PEG10 promotes progression of neuroendocrine prostate cancer","volume":"12","author":"Akamatsu","year":"2015","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.semdp.2026.151063_bib0089","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101970","article-title":"WLS-Wnt signaling promotes neuroendocrine prostate cancer","volume":"24","author":"Bland","year":"2021","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.semdp.2026.151063_bib0090","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41698-024-00599-6","article-title":"Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: expression landscape and molecular correlates","volume":"8","author":"Ajkunic","year":"2024","journal-title":"NPJ Precis Oncol"},{"issue":"4","key":"10.1016\/j.semdp.2026.151063_bib0091","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1073\/pnas.1905384117","article-title":"Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1","volume":"117","author":"Hsu","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.semdp.2026.151063_bib0092","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.canlet.2018.10.004","article-title":"Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer","volume":"440-441","author":"Chen","year":"2019","journal-title":"Cancer Lett"},{"issue":"6","key":"10.1016\/j.semdp.2026.151063_bib0093","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/S0002-9440(10)62490-X","article-title":"Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer","volume":"166","author":"Huang","year":"2005","journal-title":"Am J Pathol"},{"issue":"521","key":"10.1016\/j.semdp.2026.151063_bib0094","doi-asserted-by":"crossref","first-page":"eaax0428","DOI":"10.1126\/scitranslmed.aax0428","article-title":"Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer","author":"Li","year":"2019","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.semdp.2026.151063_bib0095","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/path.6063","article-title":"Oncofetal protein glypican-3 is a biomarker and critical regulator of function for neuroendocrine cells in prostate cancer","volume":"260","author":"Butler","year":"2023","journal-title":"J Pathol"},{"issue":"4","key":"10.1016\/j.semdp.2026.151063_bib0096","doi-asserted-by":"crossref","first-page":"586","DOI":"10.2967\/jnumed.123.266766","article-title":"Peptide binder to glypican-3 as a theranostic agent for hepatocellular carcinoma","volume":"65","author":"Lin","year":"2024","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1016\/j.semdp.2026.151063_bib0109","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S1470-2045(24)00249-3","article-title":"Imaging with [(89)Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1\/2, first-in-human trial","volume":"25","author":"Tendler","year":"2024","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.semdp.2026.151063_bib0110","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1200\/JCO-25-02693","article-title":"Systemic therapy in patients with metastatic castration-resistant prostate cancer: ASCO living guideline, version 2026.1","volume":"44","author":"Taplin","year":"2026","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.semdp.2026.151063_bib0111","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1158\/1078-0432.CCR-25-1211","article-title":"Safety and efficacy of tarlatamab in patients with neuroendocrine prostate cancer: results from the phase 1b DeLLpro-300 study","volume":"31","author":"Aggarwal","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.semdp.2026.151063_bib0101","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13045-023-01464-y","article-title":"Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer","volume":"16","author":"Rudin","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.semdp.2026.151063_bib0112","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41698-025-01131-0","article-title":"The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer","volume":"9","author":"Lin","year":"2025","journal-title":"NPJ Precis Oncol"},{"issue":"2","key":"10.1016\/j.semdp.2026.151063_bib0113","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1158\/1535-7163.MCT-25-0453","article-title":"Preclinical activity of the DLL3-targeted T-cell engager MK-6070 in neuroendocrine prostate cancer","volume":"25","author":"Ku","year":"2026","journal-title":"Mol Cancer Ther"}],"container-title":["Seminars in Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740257026000833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740257026000833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:54:50Z","timestamp":1793310890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740257026000833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":101,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0740257026000833"],"URL":"https:\/\/doi.org\/10.1016\/j.semdp.2026.151063","relation":{},"ISSN":["0740-2570"],"issn-type":[{"value":"0740-2570","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular features of prostate cancer with neuroendocrine differentiation","name":"articletitle","label":"Article Title"},{"value":"Seminars in Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semdp.2026.151063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"151063"}}